Hollis-Eden Pharmaceuticals related Press Releases
Hollis-Eden Pharmaceuticals Presents Additional Positive Findings for APOPTONETM (HE3235) in Preclinical Models of Castration-Re
Hollis-Eden Pharmaceuticals Presents Additional Positive Findings for APOPTONETM (HE3235) in Preclinical Models of Castration-Resistant Prostate Cancer September 29, 2008 SAN DIEGO--(BUSINESS Read more...
PRESS RELEASE: Hollis-Eden Pharmaceuticals Presents Positive Results with Novel Drug Candidate HE3235
Hollis-Eden Pharmaceuticals Presents Positive Results with Novel Drug Candidate HE3235 in Model of Hormone Independent Prostate Cancer SAN DIEGO -- Oct 4, 2007 - Hollis-Eden Pharmaceuticals the Read more...
PRESS RELEASE: Hollis-Eden Pharmaceuticals Presents HE3235 Update at ASCO Breast Cancer Symposium
Hollis-Eden Pharmaceuticals Presents HE3235 Update at ASCO Breast Cancer Symposium Preclinical Data Show Lasting Anti-Tumor Effect of Novel Drug Candidate SAN DIEGO -- Hollis-Eden Pharmaceuticals, Read more...
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
